DEXA Scan Guidelines for Osteoporosis Screening

General Screening Recommendations

The US Preventive Services Task Force recommends DEXA screening for all women aged 65 years or older and selective screening for postmenopausal women younger than 65 years who have elevated risk of osteoporosis based on clinical risk assessment 1
Women aged 65 years and older should undergo routine DEXA screening regardless of risk factors 1, 2
Men aged 70 years and older should undergo routine DEXA screening 3, 4
The American Academy of Family Physicians recommends against routine DEXA screening in women younger than 65 years and men younger than 70 years with no risk factors 1

High-Risk Groups Requiring Earlier Screening

Adults with a previous fragility fracture should undergo DEXA screening 3
Individuals on long-term glucocorticoid therapy should undergo DEXA screening 3
Individuals with medical conditions associated with bone loss, such as hyperparathyroidism or hypogonadism, should undergo DEXA screening 3
Individuals taking medications associated with bone loss should undergo DEXA screening 3, 5
Individuals with spinal cord injuries should undergo DEXA screening as soon as medically stable 3
Individuals undergoing androgen deprivation therapy for prostate cancer should undergo DEXA screening 3

Vertebral Fracture Assessment (VFA) Indications

VFA or standard radiography is recommended for individuals with a T-score < -1.0 and one or more of the following: women aged ≥70 years or men aged ≥80 years, historical height loss >4 cm, self-reported but undocumented prior vertebral fracture, or oral glucocorticoid therapy equivalent to ≥5 mg prednisone daily for ≥3 months 3
The Bone Health & Osteoporosis Foundation recommends VFA for women aged 65+ years with T-score ≤-1.0 at femoral neck, women aged 70+ years or men aged 80+ years with T-score ≤-1.0 at lumbar spine, total hip, or femoral neck, and men aged 70-79 years with T-score ≤-1.5 at lumbar spine, total hip, or femoral neck 3

Screening Intervals

For individuals with normal bone density or mild osteopenia, repeat DEXA in 2-3 years 6
For individuals with osteoporosis or on treatment, repeat DEXA in 1-2 years to monitor treatment effectiveness 3, 6
For individuals with spinal cord injuries, follow-up DEXA at 1-2 year intervals 3

Special Considerations

Z-scores should be calculated using reference data conforming with the individual's gender identity for transgender individuals 3
Post-pubertal transgender youth on gonadotropin-releasing hormone without sex steroid therapy may be at risk for decreasing bone density 3

Fracture Risk Assessment

FRAX or other validated tools should be used to calculate 10-year fracture risk 5
In men with prostate cancer on androgen deprivation therapy, "secondary osteoporosis" can be selected in FRAX when femoral neck BMD is not available 3

DEXA Scan Timing for 65-Year-Old with Normal Bone Density

Rationale for Extended Screening Intervals

The US Preventive Services Task Force (USPSTF) indicates that evidence is lacking about optimal intervals for repeated screening, and whether repeated screening is necessary in a woman with normal BMD 7, 8
A prospective study of 4,124 women 65 years or older found that neither repeated BMD measurement nor the change in BMD after eight years was more predictive of subsequent fracture risk than the original measurement 7
Due to limitations in testing precision, a minimum of two years is needed to reliably measure a change in BMD; however, longer intervals may be necessary to improve fracture risk prediction 7
Cohort studies evaluating screening intervals suggest that repeating BMD testing at an interval of 4 to 8 years does not result in additional accuracy in predicting fractures 9

Factors Affecting Screening Intervals

BMD measurements do not need to be repeated routinely in patients with osteopenia unless the baseline T-score is < -2.0 or risk factors develop 10

Special Considerations for Higher Risk Individuals

Shorter intervals between testing (1-2 years) are appropriate for patients at high risk for accelerated bone loss, such as those on glucocorticoid therapy 10
The transition to osteoporosis occurs over shorter intervals for individuals with lower baseline T scores and older age (about 5 years for women with a baseline T score in the -1.50 to -1.99 range versus almost 17 years for those with normal BMD) 9

Clinical Approach for a 65-Year-Old with Normal BMD

A 65-year-old white woman with no other risk factors has a 9.3% 10-year risk of any osteoporotic fracture 7
Assess for new risk factors at each clinical encounter, including development of conditions associated with bone loss, new medications that affect bone metabolism, and height loss > 4 cm or kyphosis development 10, 11

Common Pitfalls to Avoid

Repeating DEXA scans too frequently (less than 2 years apart) in patients with normal BMD is discouraged as it exposes patients to unnecessary radiation and costs without clinical benefit 10
Failing to recognize that scan intervals <1 year are not recommended under any circumstances 10
Overlooking the development of new risk factors that might warrant earlier repeat testing 10
Not considering that different DXA machines may exhibit variation in measurements unless cross-calibration has been performed 10

DEXA Scan Recommendations for High-Risk Individuals

Indications for DEXA Screening

The American College of Radiology recommends DEXA screening for individuals receiving or expected to receive glucocorticoid therapy for >3 months, regardless of age 12, 13
The American College of Radiology recommends DEXA screening for individuals on androgen deprivation therapy for prostate cancer, regardless of age 12, 13
The American College of Radiology recommends DEXA screening for individuals on aromatase inhibitor therapy, regardless of age 12, 13
The American College of Radiology recommends DEXA screening for individuals on chronic anticonvulsant drugs or chronic heparin therapy, regardless of age 12, 13
The American College of Radiology recommends DEXA screening for hypogonadal men >18 years of age and men with surgically or chemotherapeutically induced castration 12, 13
The American College of Radiology recommends DEXA screening for individuals with hyperparathyroidism, hyperthyroidism, or Cushing syndrome 12, 13
The American College of Radiology recommends DEXA screening for individuals with chronic alcoholism or established cirrhosis 12, 13
The American College of Radiology recommends DEXA screening for individuals with rheumatoid arthritis or other chronic inflammatory arthritides 13
The American College of Radiology recommends DEXA screening for individuals with eating disorders including anorexia nervosa and bulimia 13
The American College of Radiology recommends DEXA screening for individuals with organ transplantation 13
The American College of Radiology recommends DEXA screening for individuals with gastrointestinal malabsorption, malnutrition, sprue, or vitamin D deficiency 12, 13
The American College of Radiology recommends DEXA screening for individuals with prolonged immobilization 13

Scan Technique

The American College of Radiology recommends scanning both lumbar spine and bilateral hips in all patients 12, 13
The American College of Radiology recommends considering Vertebral Fracture Assessment (VFA) during the same session for patients with T-score <-1.0 and one or more of the following: women ≥70 years or men ≥80 years, historical height loss >4 cm, self-reported prior vertebral fracture, or glucocorticoid therapy ≥5 mg prednisone daily for ≥3 months 12, 13

DEXA Screening Recommendations for Premenopausal Women on Medroxyprogesterone Acetate

Evidence for Depot Medroxyprogesterone Acetate (DMPA)

Athletes receiving depot medroxyprogesterone acetate for ≥ 6 months should be considered for DEXA testing because this formulation is associated with measurable bone loss. [14][15]

Standard DEXA Screening Guidelines for Premenopausal Women (American College of Radiology)

Routine DEXA screening is not recommended for premenopausal women younger than 65 years who have no osteoporosis risk factors. 16
DEXA is indicated only when a premenopausal woman has specific medical conditions (e.g., chronic renal failure, rheumatoid arthritis, organ transplantation, prolonged immobilization) or endocrine disorders (e.g., hyperparathyroidism, hyperthyroidism, Cushing syndrome) that affect bone mineral density. 16
Glucocorticoid therapy lasting longer than 3 months is a recognized indication for DEXA in this population. [16][17]
Long‑term use of medications known to adversely affect BMD—specifically depot medroxyprogesterone acetate—warrants DEXA evaluation. 16

Risk‑Factor Assessment and Decision Algorithm (American College of Radiology)

Assess for standard osteoporosis risk factors before ordering DEXA:
If no risk factors are present, do not order DEXA. 16
If one or more risk factors are present, obtain DEXA of the lumbar spine, hip, and femoral neck. [16][17]

Situations Warranting DEXA in Women on Oral Medroxyprogesterone Acetate

Development of amenorrhea lasting > 6 months (suggesting a new hypo‑estrogenic state) triggers DEXA screening. [14][15]
Initiation of glucocorticoid therapy expected to exceed 3 months requires DEXA. [16][17]
Emergence of an eating disorder, significant weight loss (> 10 % in one month), or BMI < 17.5 kg/m² mandates DEXA evaluation. [14][15]
Occurrence of a fragility fracture is an indication for DEXA. 17
Diagnosis of any secondary osteoporosis condition (e.g., hyperparathyroidism, hyperthyroidism, chronic renal failure) calls for DEXA. 16

Common Pitfalls (American College of Radiology)

Do not conflate depot and oral medroxyprogesterone acetate; bone‑loss data apply only to the depot formulation. [14][15]
Avoid ordering DEXA “just to be safe” in low‑risk premenopausal women, as intervals < 2 years cannot reliably detect meaningful change. 18
Do not apply the age ≥ 65 years screening threshold to premenopausal women; this threshold is reserved for postmenopausal populations. 16

The absence of the above risk factors, together with the use of oral (not depot) medroxyprogesterone acetate, does not meet evidence‑based criteria for DEXA screening in premenopausal women. 16

DEXA Screening and Management Guidelines for Post‑menopausal Women with High‑Risk Features

1. Screening Indications

Women aged ≥ 65 years should undergo routine bone‑density screening, independent of other risk factors; the USPSTF assigns a Grade B recommendation (strong evidence of moderate net benefit) for this practice. 19
Detection of osteopenia on any plain radiograph (e.g., shoulder X‑ray) is a red‑flag that mandates a formal DEXA of the lumbar spine and hips, because radiographs only reveal bone loss after 30‑40 % of mineral density is lost. 20
Low body weight (or a small skeletal frame) is recognized by the American College of Radiology as an independent criterion for earlier DEXA screening in post‑menopausal women. 20
Chronic inflammatory arthritis (e.g., rheumatoid arthritis) provides an additional indication for DEXA regardless of age, due to accelerated bone loss from inflammation and glucocorticoid use. 20

2. Recommended DEXA Protocol

Scan Sites

Perform DEXA of both the lumbar spine (L1‑L4) and bilateral hips (total hip and femoral neck) to capture possible discordance, which occurs in up to 30 % of patients. 20

Interpretation

Use T‑scores (comparison with young‑adult peak bone mass) for diagnosis in post‑menopausal women; Z‑scores are not appropriate and may underestimate fracture risk. 20

Vertebral Fracture Assessment (VFA)

Include VFA during the same DEXA session for patients who meet any of the following: age ≥ 70 years, anticipated T‑score < ‑1.0, or small body frame. 20
VFA identifies asymptomatic vertebral compression fractures in ≈ 20‑30 % of such high‑risk patients, and the presence of these fractures markedly raises future fracture risk independent of BMD. 20

3. Management Based on DEXA Results

Osteoporosis (T‑score ≤ ‑2.5)

Initiate bisphosphonate therapy as first‑line pharmacologic treatment. 21
Provide calcium (≈ 1200 mg/day) and vitamin D (800‑1000 IU/day) supplementation. 21
Schedule repeat DEXA in 1‑2 years to assess treatment response.

Osteopenia (T‑score ‑1.0 to ‑2.4)

Calculate 10‑year fracture probability with the FRAX tool.
If the 10‑year major osteoporotic fracture risk ≥ 20 % or hip fracture risk ≥ 3 %, start pharmacologic therapy; otherwise, repeat DEXA in 2‑3 years. 21

Vertebral Fracture Findings (VFA)

Grade 2 or 3 vertebral fractures (≥ 30 % height loss) constitute an absolute indication for pharmacologic treatment, even if the T‑score is in the osteopenic range. 20
Grade 1 fractures (20‑25 % height loss) require clinical correlation; treatment is generally recommended when multiple fractures are present. 20

4. Common Pitfalls to Avoid

Do not attribute osteopenia seen on imaging to osteoarthritis or normal aging; these are separate pathologies requiring dedicated evaluation. 20
Do not postpone DEXA screening; patients meeting any high‑risk criteria should be scanned promptly. 20
Do not limit scanning to a single site (spine or hip alone), as this can miss up to 30 % of osteoporosis cases. 20
Do not omit VFA to save time; the additional radiation dose is minimal (~3 µSv) and the diagnostic yield is clinically significant. 20
Do not use Z‑scores for diagnosis in post‑menopausal women; T‑scores remain the standard. 20